Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis

Lancet

Volumn 358, Issue 9298, 2001, Pages 2014-2016

  Hamilton, Joshua W ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; ABC TRANSPORTER; AMINOGLYCOSIDE ANTIBIOTIC AGENT; DOXORUBICIN; DYSTROPHIN; GENTAMICIN; MESSENGER RNA; PANCREAS ENZYME; PHENYLALANINE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL MODEL; CELL MEMBRANE POTENTIAL; CHLORIDE TRANSPORT; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME REPLACEMENT; EPITHELIUM CELL; FRAMESHIFT MUTATION; GENE DELETION; GENE MUTATION; GENE THERAPY; HUMAN; LUNG FUNCTION; LUNG INFECTION; MISSENSE MUTATION; MORTALITY; MOUSE; NONHUMAN; NOTE; PH; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN TRANSPORT; RESPIRATORY EPITHELIUM; SODIUM TRANSPORT; STOP CODON;

EID: 0035894583     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)07138-0     Document Type: Note

References (17)

1. i on the cellular retention of doxorubicin analyzed via a comparison between cystic fibrosis transmembrane conductance regulator (CFTR) and multidrug resistance (MDR) transfectants
2. CFTR as a cAMP-dependent regulator of sodium channels
3. Regulation of ion channels by ABC transporters that secrete ATP
4. Cystic fibrosis: Genotypic and phenotypic variations
5. Cystic fibrosis
6. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene
7. Defective protein folding as a basis of human disease
8. Understanding how cystic fibrosis mutations cause a loss of Cl channel function
9. 1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator ΔF508 mutation
10. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF508-CFTR
11. Novel pharmacologic therapies for cystic fibrosis
12. Increased functional cell surface expression of CFTR and ΔF508-CFTR by the anthracycline doxorubicin
13. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations
14. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line
15. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mds mice
16. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis
17. Pharmacogenomics: Will it change the field of medicine?